Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    J Cell Biochem. 2006 Feb 1;97(2):226-32.

    Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.

    Source

    Department of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, New York 14642, USA. Allen.Anandarajah@urmc.rochester.edu

    Abstract

    Focal bone loss around inflamed joints in patients with autoimmune disease, such as rheumatoid arthritis, remains a serious clinical problem. The recent elucidation of the RANK/RANK-ligand/OPG pathway and its role as the final effector of osteoclastogenesis and bone resorption has brought a tremendous understanding of the pathophysiology of inflammatory bone loss, and has heightened expectation of a novel intervention. Here, we review the etiology of inflammatory bone loss, the RANK/RANK-ligand/OPG pathway, and the clinical development of anti-RANK-ligand therapy.

    Copyright 2005 Wiley-Liss, Inc.

    PMID:
    16240334
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for John Wiley & Sons, Inc.

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk